Patents by Inventor Junji Kamon
Junji Kamon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9556187Abstract: This disclosure relates to novel tricyclic pyrimidine compounds and tricyclic pyridine compounds having JAK inhibitory activities. A tricyclic heterocyclic compound represented by the formula (Ib), wherein the rings Ab and Bb, Xb, Yb, R1b, R2b, R3b, L1b, L2b, L3b and nb are as defined in the specification.Type: GrantFiled: October 2, 2015Date of Patent: January 31, 2017Assignee: NISSAN CHEMICAL INDUSTRIES, LTD.Inventors: Keishi Hayashi, Tsuneo Watanabe, Koji Toyama, Junji Kamon, Masataka Minami, Miyuki Uni, Mariko Nasu
-
Publication number: 20160102102Abstract: This disclosure relates to novel tricyclic pyrimidine compounds and tricyclic pyridine compounds having JAK inhibitory activities. A tricyclic heterocyclic compound represented by the formula (Ib), wherein the rings Ab and Bb, Xb, Yb, R1b, R2b, R3b, L1b, L2b, L3b and nb are as defined in the specification.Type: ApplicationFiled: October 2, 2015Publication date: April 14, 2016Applicant: NISSAN CHEMICAL INDUSTRIES, LTD.Inventors: Keishi HAYASHI, Tsuneo Watanabe, Koji Toyama, Junji Kamon, Masataka Minami, Miyuki Uni, Mariko Nasu
-
Patent number: 9216999Abstract: Novel tricyclic pyrimidine compounds and tricyclic pyridine compounds having JAK inhibitory activities are provided. A tricyclic heterocyclic compound represented by the formula (Ia): wherein the rings Aa and Ba, Xa, Ya, R1a, R2a, R3a, L1a L2a, L3a and na are as defined in the description.Type: GrantFiled: August 10, 2012Date of Patent: December 22, 2015Assignee: Nissan Chemical Industries, Ltd.Inventors: Keishi Hayashi, Tsuneo Watanabe, Koji Toyama, Junji Kamon, Masataka Minami, Miyuki Uni, Mariko Nasu
-
Publication number: 20140200344Abstract: Novel tricyclic pyrimidine compounds and tricyclic pyridine compounds having JAK inhibitory activities are provided. A tricyclic heterocyclic compound represented by the formula (Ia): wherein the rings Aa and Ba, Xa, Ya, R1a, R2a, R3a, L1a L2a, L3a and na are as defined in the description.Type: ApplicationFiled: August 10, 2012Publication date: July 17, 2014Applicant: Nissan Chemical Industries, Ltd.Inventors: Keishi Hayashi, Tsuneo Watanabe, Koji Toyama, Junji Kamon, Masataka Minami, Miyuki Uni, Mariko Nasu
-
Patent number: 8440666Abstract: Novel pyridazinone compounds of formula (I), which inhibit the purinergic P2X7 receptor and are useful for prevention, therapy and improvement of inflammatory and immunological diseases.Type: GrantFiled: October 30, 2008Date of Patent: May 14, 2013Assignee: Nissan Chemical Industries, Ltd.Inventors: Yukihiro Shigeta, Yutaka Hirokawa, Hiroshi Nagai, Kei Nagae, Tsuneo Watanabe, Megumi Io, Yusuke Shintani, Junji Kamon, Masato Horikawa, Kazuya Takeuchi
-
Patent number: 8252584Abstract: The object is to isolate and identify human and mouse adiponectin receptors, to provide a novel protein having adiponectin binding ability, and to provide a screening method and screening kit for a ligand, agonist and antagonist to an adiponectin receptor using such protein. To achieve this object, a protein is used, as novel protein having adiponectin binding ability, that is (a) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8, or (b) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8 with one or more amino acids deleted, replaced or added, and having adiponectin binding ability.Type: GrantFiled: June 3, 2011Date of Patent: August 28, 2012Assignees: Toudai TLO, Ltd., Nissan Chemical Industries, Ltd.Inventors: Takashi Kadowaki, Toshimasa Yamauchi, Ryozo Nagai, Junji Kamon
-
Publication number: 20120027760Abstract: The object is to isolate and identify human and mouse adiponectin receptors, to provide a novel protein having adiponectin binding ability, and to provide a screening method and screening kit for a ligand, agonist and antagonist to an adiponectin receptor using such protein. To achieve this object, a protein is used, as novel protein having adiponectin binding ability, that is (a) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8, or (b) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8 with one or more amino acids deleted, replaced or added, and having adiponectin binding ability.Type: ApplicationFiled: June 3, 2011Publication date: February 2, 2012Applicants: Nissan Chemical Industries, Ltd., TOUDAI TLO, Ltd.Inventors: Takashi KADOWAKI, Toshimasa Yamauchi, Ryozo Nagai, Junji Kamon
-
Patent number: 7977459Abstract: The object is to isolate and identify human and mouse adiponectin receptors, to provide a novel protein having adiponectin binding ability, and to provide a screening method and screening kit for a ligand, agonist and antagonist to an adiponectin receptor using such protein. To achieve this object, a protein is used, as novel protein having adiponectin binding ability, that is (a) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8, or (b) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8 with one or more amino acids deleted, replaced or added, and having adiponectin binding ability.Type: GrantFiled: January 29, 2009Date of Patent: July 12, 2011Assignees: TOUDAI TLO, Ltd., Nissan Chemical Industries, Ltd.Inventors: Takashi Kadowaki, Toshimasa Yamauchi, Ryozo Nagai, Junji Kamon
-
Publication number: 20110065780Abstract: The invention provides an insulin resistance improving agent and a therapeutic agent for type 2 diabetes, which contain a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin. The invention also provides a method for improving insulin resistance and treating type 2 diabetes by administering the aforementioned agent(s).Type: ApplicationFiled: October 18, 2010Publication date: March 17, 2011Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: Takashi KADOWAKI, Toshimasa Yamauchi, Junji Kamon, Hironori Waki, Ryozo Nagai, Satoshi Kimura, Motoo Tomita
-
Patent number: 7850976Abstract: The invention provides an insulin resistance improving agent and a therapeutic agent for type 2 diabetes, which contain a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin. The invention also provides a method for improving insulin resistance and treating type 2 diabetes by administering the aforementioned agent(s).Type: GrantFiled: March 3, 2008Date of Patent: December 14, 2010Assignee: Japan Science and Technology AgencyInventors: Takashi Kadowaki, Toshimasa Yamauchi, Junji Kamon, Hironori Waki, Ryozo Nagai, Satoshi Kimura, Motoo Tomita
-
Publication number: 20100286390Abstract: Novel pyridazinone compounds of formula (I), which inhibit the purinergic P2X7 receptor and are useful for prevention, therapy and improvement of inflammatory and immunological diseases.Type: ApplicationFiled: October 30, 2008Publication date: November 11, 2010Inventors: Yukihiro Shigeta, Yutaka Hirokawa, Hiroshi Nagai, Kei Nagae, Tsuneo Watanabe, Megumi Io, Yusuke Shintani, Junji Kamon, Masato Horikawa, Kazuya Takeuchi
-
Publication number: 20100120674Abstract: The invention provides an insulin resistance improving agent and a therapeutic agent for type 2 diabetes, which contain a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin. The invention also provides a method for improving insulin resistance and treating type 2 diabetes by administering the aforementioned agent(s).Type: ApplicationFiled: March 3, 2008Publication date: May 13, 2010Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: TAKASHI KADOWAKI, TOSHIMASA YAMAUCHI, JUNJI KAMON, HIRONORI WAKI, RYOZO NAGAI, SATOSHI KIMURA, MOTOO TOMITA
-
Publication number: 20100062541Abstract: The object is to isolate and identify human and mouse adiponectin receptors, to provide a novel protein having adiponectin binding ability, and to provide a screening method and screening kit for a ligand, agonist and antagonist to an adiponectin receptor using such protein. To achieve this object, a protein is used, as novel protein having adiponectin binding ability, that is (a) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8, or (b) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8 with one or more amino acids deleted, replaced or added, and having adiponectin binding ability.Type: ApplicationFiled: January 29, 2009Publication date: March 11, 2010Applicants: TOUDAI TLO, Ltd., Nissan Chemical Industries, Ltd.Inventors: Takashi Kadowaki, Toshimasa Yamauchi, Ryozo Nagai, Junji Kamon
-
Patent number: 7501490Abstract: The object is to isolate and identify human and mouse adiponectin receptors, to provide a novel protein having adiponectin binding ability, and to provide a screening method and screening kit for a ligand, agonist and antagonist to an adiponectin receptor using such protein. To achieve this object, a protein is used, as novel protein having adiponectin binding ability, that is (a) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8, or (b) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8 with one or more amino acids deleted, replaced or added, and having adiponectin binding ability.Type: GrantFiled: November 13, 2006Date of Patent: March 10, 2009Assignees: Toudai TLO, Ltd., Nissan Chemical Industries, Ltd.Inventors: Takashi Kadowaki, Toshimasa Yamauchi, Ryozo Nagai, Junji Kamon
-
Publication number: 20070054314Abstract: The object is to isolate and identify human and mouse adiponectin receptors, to provide a novel protein having adiponectin binding ability, and to provide a screening method and screening kit for a ligand, agonist and antagonist to an adiponectin receptor using such protein. To achieve this object, a protein is used, as novel protein having adiponectin binding ability, that is (a) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8, or (b) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8 with one or more amino acids deleted, replaced or added, and having adiponectin binding ability.Type: ApplicationFiled: November 13, 2006Publication date: March 8, 2007Applicants: Center for Advanced Science and Technology Incubation, Ltd., Nissan Chemical Industries, Ltd.Inventors: Takashi Kadowaki, Toshimasa Yamauchi, Ryozo Nagai, Junji Kamon
-
Publication number: 20060199761Abstract: The invention provides an insulin resistance improving agent which contains, as an active component, a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin. The invention also provides a therapeutic agent for type 2 diabetes, which contains, as an active component, a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin. The invention reverses insulin resistance induced from a high fat diet and associated with obesity, and therefore, enables treatment of type 2 diabetes, which is the most common among other types of diabetes.Type: ApplicationFiled: July 26, 2002Publication date: September 7, 2006Applicant: Japan Science And Technology AgencyInventors: Takashi Kadowaki, Toshimasa Yamauchi, Junji Kamon, Hironori Waki, Ryozo Nagai, Satoshi Kimura, Motto Tomita
-
Publication number: 20040241802Abstract: The object is to isolate and identify human and mouse adiponectin receptors, to provide a novel protein having adiponectin binding ability, and to provide a screening method and screening kit for a ligand, agonist and antagonist to an adiponectin receptor using such protein. To achieve this object, a protein is used, as novel protein having adiponectin binding ability, that is (a) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8, or (b) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8 with one or more amino acids deleted, replaced or added, and having adiponectin binding ability.Type: ApplicationFiled: March 11, 2004Publication date: December 2, 2004Applicants: Center for Advanced Science and Technology Incubation, Ltd., Nissan Chemical Industries, Ltd.Inventors: Takashi Kadowaki, Toshimasa Yamauchi, Ryozo Nagai, Junji Kamon